Chmátalová Zuzana, Vyhnálek Martin, Laczó Jan, Hort Jakub, Skoumalová Alice
Department of Medical Chemistry and Clinical Biochemistry, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic.
J Cell Mol Med. 2016 Jul;20(7):1367-72. doi: 10.1111/jcmm.12824. Epub 2016 Mar 16.
Alzheimer's disease (AD) is a severe neurodegenerative disorder characterized by cognitive decline. Prodromal stage of AD, also called mild cognitive impairment (MCI), especially its amnestic type (aMCI), precedes dementia stage of AD. There are currently no reliable diagnostic biomarkers of AD in the blood. Alzheimer's disease is accompanied by increased oxidative stress in brain, which leads to oxidative damage and accumulation of free radical reaction end-products. In our study, specific products of lipid peroxidation in the blood of AD patients were studied. Lipophilic extracts of erythrocytes (AD dementia = 19, aMCI = 27, controls = 16) and plasma (AD dementia = 11, aMCI = 17, controls = 16) were analysed by fluorescence spectroscopy. The level of these products is significantly increased in erythrocytes and plasma of AD dementia and aMCI patients versus controls. We concluded that oxidative stress end-products are promising new biomarkers of AD, but further detailed characterisation of these products is needed.
阿尔茨海默病(AD)是一种以认知功能衰退为特征的严重神经退行性疾病。AD的前驱期,也称为轻度认知障碍(MCI),尤其是遗忘型(aMCI),先于AD的痴呆阶段出现。目前血液中尚无可靠的AD诊断生物标志物。阿尔茨海默病伴有大脑氧化应激增加,这会导致氧化损伤和自由基反应终产物的积累。在我们的研究中,对AD患者血液中脂质过氧化的特定产物进行了研究。通过荧光光谱法分析了红细胞(AD痴呆患者 = 19例,aMCI患者 = 27例,对照组 = 16例)和血浆(AD痴呆患者 = 11例,aMCI患者 = 17例,对照组 = 16例)的亲脂性提取物。与对照组相比,AD痴呆和aMCI患者的红细胞和血浆中这些产物的水平显著升高。我们得出结论,氧化应激终产物是有前景的新型AD生物标志物,但需要对这些产物进行进一步详细的表征。